The Annexure

News to 16 October 2026 ·

Desk›Chemicals› Epigral Ltd

Epigral Ltd

BSE 543332 · NSE EPIGRAL · ISIN INE071N01016 · Group B · Active

Commodities › Chemicals › Chemicals & Petrochemicals › Specialty Chemicals

₹1,231.80

+1.93%

BSE close, 28 August 2026

Market cap

₹5,314.15 cr

4.3 cr shares · Small cap

Free float

₹1,654.98 cr

as published

P/E · P/B

19.6× · 3.80×

EPS ₹63.00 · BV ₹324.16

FY25-26 rev / PAT

2,527.18 / 333.01

₹ cr, as filed

Filings, window

17

5 selected · 29%

Regime

Reg 30

Sch. III Part A

Price 52-week, BSE

52-WK LOW ₹806.20 52-WK HIGH ₹1,889.95 ₹1,231.80 39% of range
Against 52-week high-34.8%
Against 52-week low+52.8%
Day change+1.93%
Size bandSmall cap
Index membershipNone

Valuation as published by BSE

Earnings per share₹63.00
Price / earnings19.55×
Price / book3.80×
Book value — derived, price ÷ P/B₹324.16
Return on equity19.42%
Operating margin25.99%
Net margin14.06%

Consistency check

P/B ÷ P/E, which must equal ROE
19.44%
ROE as published
19.42%

Results ₹ crore, as filed

RevenueNet profit one scale across all three periods, ₹ crore

PeriodRevenue ₹cr Net profit ₹cr EPS ₹OPM NPM
Jun-26 · Q 705.36 99.18 22.99 25.99% 14.06%
Mar-26 · Q 736.16 81.93 18.99 22.82% 11.13%
FY25-26 2,527.18 333.01 77.19 23.03% 13.18%

Quarter on quarter

Revenue, quarter on quarter
-4.2%
Net profit, quarter on quarter
+21.1%
Operating margin, quarter on quarter
+317 bps

Disclosure profile 17 filings in the window

0 median 16.0 sector max 59 17 63th percentile of 300 Chemicals filers
Shaded is the middle half of the sector, 12 to 20 filings. Measured against the 300 Chemicals companies that filed at all in this window — companies with no filings are excluded, so this is a percentile against filers rather than against the sector.
TagFilings
Selected
Board Outcome1
Concall Transcript1
Investor Presentation1
Press Release1
Results1
Selected sub-total5
Procedural
Analyst / Investor Meet7
Newspaper Publication2
Compliance Certificate1
General1
Trading Window1
Procedural sub-total12
Total17

Disclosure regime

LODR Reg 30

Read with Schedule III Part A. An equity filer in BSE Group B, so the Regulation 30 disclosure framework and the Schedule III event list both apply.

Sources Price, day change, 52-week range — bse.quote, bse.quoteWeeklyHL, 28 August 2026 close. Market cap and free float — bse.getScripTradingStats. P/E, P/B, EPS, ROE, margins — bse.equityMetaInfo. Quarterly and annual results — bse.resultsSnapshot, standalone, as filed. Four-tier classification — data/reference/companies.csv. Filing counts and tags — the build aggregate for this window. Notes Book value is derived as price ÷ P/B; BSE does not publish it directly. Share count is derived as market cap ÷ price. Figures move between captures and between vendors, and the two are not an error in either: companies.csv carries the market cap from an earlier sweep than the snapshot above. EPS appears twice with different meanings — the figure beside P/E is the trailing one from equityMetaInfo, while the EPS in the results table is the per-period figure as filed.

Filing rhythm · 98 trading days

17 filings · 5 selected · busiest 2026-07-27

Filing rhythm · the twelve most recent

2026-07-272026-10-15

SelectedProcedural

Filings

17 in the window · 11 earlier on record

  1. 15 October 2026 ·

    Compliance Certificate

    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Epigral Limited submits Certificate under REg. 74(5) of SEBI (DP) Regulations, 2018 for quarter ended 30.09.2026.

    Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →

  2. 13 October 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Epigral Limited informs that the Company is having One-on-One Meeting with Investor / Analyst on Wednesday, 13th October, 2026.

    Company Update / Analyst / Investor Meet View filing →

  3. 28 September 2026 ·

    Trading Window

    Closure of Trading Window

    Epigral Limited submits Notice of Closure of Trading Window.

    Insider Trading / SAST / Closure of Trading Window View filing →

  4. 16 September 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Epigral Limited ('the Company') hereby informs that the officials of the Company are participating in Anand Rathi Annual Flagship Conference: G-200 Summit 2026 scheduled on 21.09.2026.

    Company Update / Analyst / Investor Meet View filing →

  5. 31 August 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Epigral Limited has informed the Exchange about Investor / Analyst Plant Visit on Thursday, 03.09.2026

    Company Update / Analyst / Investor Meet View filing →

  6. 18 August 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Epigral Limited has informed the Exchange about One-on-One Meeting with Investor / Analyst on thursday, 20.08.2026

    Company Update / Analyst / Investor Meet View filing →

  7. 7 August 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Epigral Limited hereby informs that the officials of the Company are participating in EMKAY Confluence 2026 on 12th August, 2026

    Company Update / Analyst / Investor Meet View filing →

  8. 30 July 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Epigral Limited informs that the Company is having One-on-One Meeting with Investor / Analyst on Monday, 3rd august, 2026.

    Company Update / Analyst / Investor Meet View filing →

  9. 30 July 2026 ·

    Concall Transcript

    Earnings Call Transcript

    Epigral Limited submits Transcript of Conference Call discussing Q1 FY27 Results.

    Company Update / Earnings Call Transcript View filing →

  10. 29 July 2026 ·

    Newspaper Publication

    Newspaper Publication

    Newpaper Publication - Un-Audited Financial Results for the First Quarter ended 30.06.2026

    Company Update / Newspaper Publication View filing →

  11. 29 July 2026 ·

    Newspaper Publication

    Newspaper Publication

    Newspaper Publication - Un-Audited Financial Results for the First Quarter ended 30.06.2026

    Company Update / Newspaper Publication View filing →

  12. 27 July 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Outcome

    Audio Recording of Conference Call discussing Q1 FY27 Results held on Monday, 27th July, 2026 at 5.00 p.m.

    Company Update / Analyst / Investor Meet View filing →

  13. 27 July 2026 ·

    Investor Presentation

    Investor Presentation

    Investor Presentation Q1 FY 27.

    Company Update / Investor Presentation View filing →

  14. 27 July 2026 ·

    Press Release

    Press Release / Media Release

    Press Release of Un-Audited Financual results - Q1FY27.

    Company Update / Press Release / Media Release View filing →

  15. 27 July 2026 ·

    General

    Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') - Outcome Of Board Meeting

    As part of the Company's strategic growth and expansion initiatives, it proposes to establish a new manufacturing facility for Epoxy Resin and formulations and Multi Purpose Plant at its ....

    Company Update / General View filing →

  16. 27 July 2026 ·

    Board Outcome

    Board Meeting Outcome for Outcome Of Board Meeting Held On Monday, 27Th July, 2026 And Submission Of Un-Audited Financial Results (Standalone & Consolidated) For The First Quarter Ended 30Th June, 2026.

    Outcome of Board Meeting held on Monday, 27th July, 2026 and submission of Un-Audited Financial Results (Standalone & Consolidated) for the First Quarter ended 30th June, 2026.

    Board Meeting / Outcome of Board Meeting View filing →

  17. 27 July 2026 ·

    Results

    UNAUDITED FINANCIAL RESULTS - 30.06.2026

    UNAUDITED FINANCIAL RESULTS - 30.06.2026.

    Result / Financial Results View filing →

RSS feed for Epigral Ltd · the 50 most recent filings